Gilead Sciences, Inc. (BCBA:GILD)

Argentina flag Argentina · Delayed Price · Currency is ARS
46,820
-260 (-0.55%)
Last updated: Dec 4, 2025, 12:30 PM BRT
81.65%
Market Cap 220.26T
Revenue (ttm) 39.86T
Net Income (ttm) 11.11T
Shares Out n/a
EPS (ttm) 8,802.50
PE Ratio 19.82
Forward PE 14.77
Dividend 585.78 (1.25%)
Ex-Dividend Date Sep 15, 2025
Volume 9
Average Volume 276
Open 47,260
Previous Close 47,080
Day's Range 46,560 - 47,260
52-Week Range 24,025 - 50,000
Beta n/a
RSI 51.96
Earnings Date Feb 10, 2026

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1987
Employees 17,600
Stock Exchange Buenos Aires Stock Exchange
Ticker Symbol GILD
Full Company Profile

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD Financial Statements

News

There is no news available yet.